A5087375152- HIV/AIDS Research and Interventions
- HIV Research and Treatment
- COVID-19 Clinical Research Studies
- SARS-CoV-2 and COVID-19 Research
- HIV, Drug Use, Sexual Risk
- HIV/AIDS drug development and treatment
- Long-Term Effects of COVID-19
- Monoclonal and Polyclonal Antibodies Research
- Adolescent Sexual and Reproductive Health
- Vaccine Coverage and Hesitancy
- vaccines and immunoinformatics approaches
- HIV-related health complications and treatments
- SARS-CoV-2 detection and testing
- COVID-19 and healthcare impacts
- COVID-19 epidemiological studies
- Antibiotic Use and Resistance
- Herpesvirus Infections and Treatments
- COVID-19 and Mental Health
- Immunotherapy and Immune Responses
- Sepsis Diagnosis and Treatment
- Sex work and related issues
- Intensive Care Unit Cognitive Disorders
- LGBTQ Health, Identity, and Policy
- Bacillus and Francisella bacterial research
- Hepatitis C virus research
Columbia University Irving Medical Center
2016-2025
Columbia University
2015-2025
Aaron Diamond AIDS Research Center
2021-2025
New York Hospital Queens
2018-2024
NewYork–Presbyterian Hospital
2018-2024
Office of Infectious Diseases
2017-2023
Centers for Disease Control and Prevention
2022
New York University
2021
University of Rochester
2021
Unity Health System
2021
Hydroxychloroquine has been widely administered to patients with Covid-19 without robust evidence supporting its use. We examined the association between hydroxychloroquine use and intubation or death at a large medical center in New York City. Data were obtained regarding consecutive hospitalized Covid-19, excluding those who intubated, died, discharged within 24 hours after presentation emergency department (study baseline). The primary end point was composite of time-to-event analysis....
The identification of the Omicron (B.1.1.529.1 or BA.1) variant severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in Botswana November 2021
To characterize patients with coronavirus disease 2019 (covid-19) in a large New York City medical center and describe their clinical course across the emergency department, hospital wards, intensive care units.Retrospective manual record review.NewYork-Presbyterian/Columbia University Irving Medical Center, quaternary academic City.The first 1000 consecutive positive result on reverse transcriptase polymerase chain reaction assay for severe acute respiratory syndrome 2 (SARS-CoV-2) who...
Abstract SARS-CoV-2 Omicron subvariants BA.2.12.1 and BA.4/5 have surged notably to become dominant in the United States South Africa, respectively 1,2 . These new carrying further mutations their spike proteins raise concerns that they may evade neutralizing antibodies, thereby compromising efficacy of COVID-19 vaccines therapeutic monoclonals. We now report findings from a systematic antigenic analysis these surging subvariants. is only modestly (1.8-fold) more resistant sera vaccinated...
A safe and effective vaccine for the prevention of human immunodeficiency virus type 1 (HIV-1) infection is a global priority. We tested efficacy DNA prime-recombinant adenovirus 5 boost (DNA/rAd5) regimen in persons at increased risk HIV-1 United States.
Whether a broadly neutralizing antibody (bnAb) can be used to prevent human immunodeficiency virus type 1 (HIV-1) acquisition is unclear.
BackgroundThe safety and efficacy of the AZD1222 (ChAdOx1 nCoV-19) vaccine in a large, diverse population at increased risk for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection United States, Chile, Peru has not been known.MethodsIn this ongoing, double-blind, randomized, placebo-controlled, phase 3 clinical trial, we investigated safety, efficacy, immunogenicity two doses as compared with placebo preventing onset symptomatic disease 2019 (Covid-19) 15 days or more...
Background and Aims Coronavirus disease 2019 (COVID‐19) has been associated with acute liver injury (ALI) manifested by increased enzymes in reports worldwide. Prevalence of clinical characteristics are not well defined. We aim to identify the prevalence risk factors for development COVID‐19‐associated ALI a large cohort United States. Approach Results In this retrospective study, all patients who underwent SARS‐CoV‐2 testing at three hospitals NewYork‐Presbyterian network were assessed. Of...
See editorial on page 36. Coronavirus disease 2019 (COVID-19) is a pandemic characterized by high fatality rate.1World Health Organization.https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200329-sitrep-69-covid-19.pdf?sfvrsn=8d6620fa_2Date accessed: March 29, 2020Google Scholar The incidence of COVID-19 has risen dramatically in the United States since 2020, with highest number cases country present New York City.2Gardner L et al. https://coronavirus.jhu.edu/map.html....
The COVID-19 pandemic has ravaged the globe, and its causative agent, SARS-CoV-2, continues to rage. Prospects of ending this rest on development effective interventions. Single combination monoclonal antibody (mAb) therapeutics have received emergency use authorization 1–3 , with more in pipeline 4–7 . Furthermore, multiple vaccine constructs shown promise 8 including two ~95% protective efficacy against 9,10 However, these interventions were directed toward initial SARS-CoV-2 that emerged...
Microbiota can mislead antibodies Unlike the response to many viral infections, most people do not produce capable of clearing HIV-1. Non-neutralizing that target HIV-1's envelope glycoprotein (Env) typically dominate response, which is generated by B cells cross-react with Env and intestinal microbiota. Williams et al. analyzed samples from individuals who had received a vaccine containing protein, including gp41 subunit. Most were non-neutralizing targeted gp41. The also reacted...
A surge of patients with coronavirus disease 2019 (COVID-19) presenting to New York City hospitals in March 2020 led a sharp increase blood culture utilization, which overwhelmed the capacity automated instruments. We sought evaluate utilization and diagnostic yield cultures during COVID-19 pandemic determine prevalence common etiologies bacteremia inform approach relieve overutilization. performed retrospective cohort analysis 88,201 from 28,011 at multicenter network within order volume,...
Abstract The Covid-19 pandemic has ravaged the globe, and its causative agent, SARS-CoV-2, continues to rage. Prospects of ending this rest on development effective interventions. Two monoclonal antibody (mAb) therapeutics have received emergency use authorization, more are in pipeline. Furthermore, multiple vaccine constructs shown promise, including two with ~95% protective efficacy against Covid-19. However, these interventions were directed toward initial SARS-CoV-2 that emerged 2019....
Abstract Background Patients hospitalized with coronavirus disease 2019 (COVID-19) are at increased risk of health care–associated infections (HAIs), especially prolonged hospital stays. We sought to identify incidence, antimicrobial susceptibilities, and outcomes associated bacterial/fungal secondary in a large cohort patients COVID-19. Methods evaluated adult diagnosed COVID-19 between 2 March 31 May 2020 >24 hours. Data extracted from medical records included diagnoses, vital...
Abstract We describe the characteristics of 31 people living with human immunodeficiency virus hospitalized for severe acute respiratory syndrome coronavirus 2 infection. All patients were on antiretroviral therapy and virologically suppressed at time admission. Clinical course outcomes similar to those reported in other cohorts.
Abstract The Antibody Mediated Prevention trials showed that the broadly neutralizing antibody (bnAb) VRC01 prevented acquisition of human immunodeficiency virus-1 (HIV-1) sensitive to VRC01. Using AMP trial data, here we show predicted serum neutralization 80% inhibitory dilution titer (PT 80 ) biomarker—which quantifies potency antibodies in an individual’s against HIV-1 isolate—can be used predict prevention efficacy. Similar results nonhuman primate studies, average PT 200 (meaning a...
Dengue fever is a mosquito-borne illness that places significant burden on tropical developing countries with unplanned urbanization. A surveillance system using Google Earth and GIS mapping technologies was developed in Nicaragua as management tool. Satellite imagery of the town Bluefields, captured from used to create base-map ArcGIS 9. Indices larval infestation, locations tire dumps, cemeteries, large areas standing water, etc. may act development sites, homes dengue cases collected...